Emami Limited

Industry	Con. Staples
Bloomberg	HMN IN
BSE CODE	531162

RATING	HOLD
СМР	411
Price Target	447
Potential Upside	9%

Rating Change	
Estimate Change	
Target Change	+>

Stock Info

52wk Range H/L	602/386
Mkt Capital (Rs Cr)	18657
Free float (%)	27%
Avg. Vol 1M (,000)	242
No. of Shares (Crs)	45
Promoters Pledged %	48%

Research Analyst RAJEEV ANAND

+91-22-62701229

rajeev.anand@narnolia.com

Result mixed, higher crude and Mentha prices impacted margins

3QFY19 Result update

- EMAMI has reported mixed set of numbers for Q3FY19; sales grew by 7% YoY to Rs.811 Crs (vs expec. Rs.830 Crs) with Domestic business growth of 7%, International Business (IB) growth of 18% & CSD growth of 2% on YoY basis.
- IB growth was led by better traction from SAARC & MENAP regions which grew by 40% & 26% respectively.
- Volume growth remained ~3.5%; impacted by subdued growth in BoroPlus range which got affected by delayed winters.
- Key positives for this quarter remained strong growth in segments like: KeshKing and Zandu Pancharishta which grew by 26% & 30% backed by Company's correctional steps taken for strengthening these brands.
- Gross margin contracted by 218 bps to 67.0% led by high Crude & Mentha oil prices while EBITDA margin declined 210 bps to 32.9%
- PAT de-grown by 6.6% YoY to Rs.138 Crs (vs expec. Rs.168 Crs) on account of exceptional cost of 9.8 Crs pertaining to VRS related to old unit of Kolkata, higher input prices and higher provisioning of taxes by 199 bps YoY.
- Company recently, acquired German brand Crème 21 which has strong presence in Middle East and focused markets. The brand offers skin care & body care products. . It has 9-10% of EBITDA margins; Mgmt. is looking to increase it to 15-16% with bit of restructuring & pricing.

View and Valuation

Emami's number for Q3FY19 remained mixed, sales were up by 7% YoY to Rs 811 cr(expec. Rs 830 cr) while PAT declined by 7% to Rs 138 cr(expec. Rs 168 cr). Gross margin and EBITDA margin deteriorated by 218 and 210 bps YoY largely on the back of higher crude and Mentha prices. Positive for this quarter remained strong growth from Kesh King and Zandu Pancharishta which grew by 26% and30% respectively in Q3FY19 after many quarters of subdued growth. International business has also shown strong growth of 18% backed by better traction from SAARC and MENAP. Going forward, we expect better growth from Kesh King and Zandu Pancharishta led by expansion in direct coverage and recovery in rural demand while correction in crude (declined by ~25% from Oct18-Jan19) and Mentha(declined by ~12% from its peak) prices are expected to help in maintaining margin. Presently we remain cautiously optimistic on Emamiltd and maintain our hold rating with our previous target price of 447(40xFY20e's eps).

Key Risks to our rating and target

□ Volatility in Crude & Mentha prices.

□ Increase in competitive intensity.

FY16	FY17	FY18	FY19E	FY20E
2398	2533	2531	2752	3151
687	759	719	776	927
432	451	409	450	602
364	340	306	336	502
8	7	7	7	11
-25%	-6%	-10%	10%	49%
23%	19%	15%	15%	21%
19%	23%	17%	19%	23%
36	39	44	48	53
14.5	14.5	11.8	8.6	7.8
64.3	74.7	77.8	55.5	37.2
	2398 687 432 364 8 -25% 23% 19% 36 14.5	2398 2533 687 759 432 451 364 340 8 7 -25% -6% 23% 19% 19% 23% 36 39 14.5 14.5	2398 2533 2531 687 759 719 432 451 409 364 340 306 8 7 7 -25% -6% -10% 23% 19% 15% 19% 23% 17% 36 39 44 14.5 14.5 11.8	2398 2533 2531 2752 687 759 719 776 432 451 409 450 364 340 306 336 8 7 7 7 -25% -6% -10% 10% 23% 19% 15% 15% 19% 23% 17% 19% 36 39 44 48 14.5 14.5 11.8 8.6

The views expressed above accurately reflect the personal views of the authors about the subject companies and its(their) securities. The authors have not and will not receive any compensation for providing a specific recommendation or view. Narnolia Financial Advisors Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

India Equity Analytics 1-Feb-19 Result Update



3QFY19 Results Mixed

Financials	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	YoY %	QoQ%	FY17	FY18	ΥοΥ %
Net Sales	757	617	614	628	811	7.2%	29.1%	2,533	2,531	-0.1%
Other Income	6	2	2	3	6	0.2%	77.8%	31	20	-37.3%
COGS	233	215	207	197	268	14.7%	35.8%	873	810	-7.2%
Gross Margin	69%	65%	66%	69%	67%	-2.2%	-1.6%	66%	68%	2.5%
Employee Ex.	68	58	70	71	70	2.8%	-2.1%	234	255	9.0%
Adv. Ex.	129	99	143	100	129	-0.2%	29.7%	443	470	6.1%
Other Expen.	61	72	71	71	78	26.5%	10.0%	224	277	23.7%
EBITDA	265	173	124	189	267	0.7%	40.8%	759	719	-5.2%
EBITDA Mar.	35%	28%	20%	30%	33%	-2.10%	2.7%	30%	28%	-1.5%
Dep. & amor.	80	81	84	81	79	-1.0%	-2.8%	309	311	0.7%
EBIT	185	92	40	108	187	1%	73.7%	451	409	-9.3%
Interest	9	7	5	4	6	-33%	42.2%	58	34	-40.9%
PBT	181	88	37	107	187	3.2%	75.1%	424	394	-7%
Exceptional	-	-	-	-	10	-	-	-	-	0.0%
Тах	34	27	10	24	39	14.2%	61.1%	84	86	3%
PAT	147	60	26	82	138	-6.6%	66.8%	340	306	-10%
PAT Margin	19%	10%	4%	13%	17%	-2.5%	3.8%	13%	12%	-1.3%

Strategy for brand strengthening yielded better results

KeshKing grew by 26% & Zandu Pancharishta grew by 30% in Q3 led by correctional steps taken for strengthening of KeshKing & Zandu Pancharishta yielded good results. Management was aggressive in launching the applicator for better hair growth. Company increased prices to maintain margin in applicator pack. KeshKing shampoo has done exceedingly well led by reduced prices; its growth was over 100% for this quarter.

Gross Margin was impacted due to higher crude & Mentha Prices

Gross margin deteriorated by 218 bps to 67.0% led by sharp increase in Crude & Menthol oil prices. Prices of raw material have softened incurrently & company is hoping to maintain gross margins in Q4 on YoY basis. Similarly, EBITDA margin declined 210 bps to 32.9%. Company also reduced Employee Exp. & Adv. Exp. by 37 bps & 117 bps to 8.6% & 15.9% respectively while other expenses increased by 146 bps to 9.6%.

Concall Highlights

- Rural is doing slightly better than urban.
- > Domestic business grew by 7% while volume growth remained 3-3.5% in Q3FY19.
- IB Sales grew by 18% led by good performance from SAARC & MENAP regions which grew by 40% & 26% respectively. MENA, SAARC & CIS are going to be the major part international business in upcoming quarters.
- For KeshKing Amortization is expected to be 60 Crs till June 2020 & post that it would be 90 Crs per year for next 5 years.
- Company is still seeing opportunity for more growth in Pancharishta and is extensively focusing on it.
- Exceptional cost of 9.8 Crs came in this quarter pertaining to VRS related to old unit of Kolkata.
- > Company would be maintaining Adv. Exp. depending on market scenario around 18-19%.
- EMAMI acquired German brand Crème 21 with strong presence in Middle East and focused markets. Mgmt. planned to leverage their distribution network to extend Crème 21 in countries like Middle Eastern countries & CIS.
- Crème growth was stagnant for last 3-4years as they haven't invested in it. It has 9-10% of EBITDA margins; Mgmt. is looking to increase it to 15-16% with bit of restructuring & pricing. It has high manufacturing cost as entire manufacturing in Germany, for now Emami would continue the same.
- Promoters Pledge increased to 47.5% due to share price correction, company maintained it to 30-40% previously. Company is working on reducing pledge soon.
- Boroplus, Fair & Handsome & Balms maintained their market leadership in with Market share of 72.7%, 63.7% and 54.4% respectively.
- KeshKing Company engaged BCG and on their recommendation, Company implemented the new strategy of BCG which yielded good results. MGMT was aggressive for launching the applicator for better hair growth.

EMAMILTD

Exhibit: Domestic Volume growth

Volume growth of 3.5% led revival of Kesh King & Pancharishta.




Exhibit: Sales and Sales Growth

Sales for the quarter grew by 7% YoY to Rs.811 Crs (vs expect. of Rs.830 Crs).




Exhibit: Gross and EBITDA Margin

Gross margin contracted by 218 bps to 67.0% led by high oil prices & EBITDA margin declined 210 bps to 32.9%.




Exhibit: PAT and PAT Growth

PAT de-grown by 6.6% YoY to Rs.138 Crs (vs expec. Rs.168 Crs).




Exhibit: Expenses

Emp. & Adv. ex. declined by 37 bps & 117 bps to 8.6% & 15.9% respectively while other ex was up by 146 bps.





Exhibit: Return on equity

ROE is expected to improve by 28 bps and 543 bps in FY19 and FY20 respectively.



Financial Details

Balance Sheet

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Share Capital	15	23	23	23	23	23	45	45
Reserves	762	909	1,208	1,589	1,732	1,991	2,123	2,354
Networth	777	932	1,231	1,612	1,755	2,014	2,168	2,399
Debt	86	22	19	671	173	326	253	178
Other Non Current Liab	21	22	41	46	80	73	73	73
Total Capital Employed	863	954	1,250	2,283	1,928	2,340	2,421	2,577
Net Fixed Assets (incl CWIP)	440	408	478	2,037	2,011	1,828	1,592	1,360
Non Current Investments	7	7	7	35	94	186	186	186
Other Non Current Assets	39	42	48	114	49	86	86	86
Non Current Assets	485	457	532	2,187	2,155	2,100	1,864	1,632
Inventory	114	141	127	151	179	194	211	241
Debtors	112	79	103	131	97	156	170	194
Cash & Bank	282	270	354	108	50	16	33	35
Other Current Assets	223	355	561	115	132	271	670	996
Current Assets	731	846	1,144	505	458	701	1,084	1,467
Creditors	102	143	193	249	185	242	263	301
Provisions	165	121	112	50	59	62	68	77
Other Current Liabilities	65	62	80	65	361	82	120	68
Curr Liabilities	332	326	385	363	605	388	453	448
Net Current Assets	399	519	759	142	(147)	313	631	1,018
Total Assets	1,216	1,302	1,676	2,692	2,613	2,801	2,947	3,098

Income Statement

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Revenue from Operation	1,699	1,821	2,217	2,398	2,533	2,531	2,752	3,151
Change (%)		7%	22%	8%	6%	0%	9%	14%
EBITDA	444	505	535	687	759	719	776	927
Change (%)			6%	28%	10%	-5%	8%	19%
Margin (%)	26%	28%	24%	29%	30%	28%	28%	29%
Depr & Amor.	124	96	34	255	309	311	326	325
EBIT	320	409	501	432	451	409	450	602
Int. & other fin. Cost	7	5	5	54	58	34	22	16
Other Income	56	62	96	44	31	20	15	42
EBT	369	466	592	423	424	394	443	628
Exp Item	-	(9)	-	-	-	-	(10)	-
Тах	54	55	107	60	84	86	95	126
Minority Int & P/L share of Ass.	(0)	(0)	(0)	(0)	(0)	-	-	-
Reported PAT	315	402	486	364	340	306	336	502
Adjusted PAT	315	410	486	364	340	306	344	502
Change (%)		30%	18%	-25%	-6%	-10%	12%	46%
Margin(%)	19%	23%	22%	15%	13%	12%	12%	16%

Financial Details

Key Ratios

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
ROE	40%	43%	39%	23%	19%	15%	15%	21%
ROCE	37%	43%	40%	19%	23%	17%	19%	23%
Asset Turnover	1	1	1	1	1	1	1	1
Debtor Days	24	16	17	20	14	22	22	22
Inv Days	24	28	21	23	26	28	28	28
Payable Days	22	29	32	38	27	35	35	35
Int Coverage	49	76	98	8	8	12	20	38
P/E	29	25	47	64	75	78	56	37
Price / Book Value	12	11	18	15	14	12	9	8
EV/EBITDA	20	29	42	34	33	33	24	20
FCF per Share	5	8	9	9	10	10	14	15
Div Yield	1%	2%	1%	0%	1%	1%	1%	1%

Cash Flow Statement

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
РВТ	369	466	592	423	424	394	431	628
(inc)/Dec in Working Capital	13	60	73	(56)	23	(61)	22	(83)
Non Cash Op Exp	28	41	31	263	314	311	326	325
Int Paid (+)	(31)	(38)	(52)	43	56	34	22	16
Tax Paid	(50)	(77)	(96)	(96)	(71)	(81)	(95)	(126)
others	(5)	(24)	(15)	(15)	(16)	(9)	-	-
CF from Op. Activities	323	428	534	562	730	588	706	761
(inc)/Dec in FA & CWIP	(85)	(65)	(110)	(1,816)	(285)	(124)	(90)	(93)
Free Cashflow	238	363	424	(1,255)	444	464	616	667
(Pur)/Sale of Inv	(78)	(138)	(284)	429	(76)	(240)	(387)	(303)
others	39	61	160	81	64	84	-	-
CF from Inv. Activities	(124)	(142)	(234)	(1,306)	(297)	(279)	(476)	(397)
inc/(dec) in NW	-	-	-	-	-	-	-	-
inc/(dec) in Debt	41	75	2	636	(198)	(184)	(73)	(75)
Int. Paid	7	5	(5)	(52)	(58)	(34)	(22)	(16)
Div Paid (inc tax)	140	221	(212)	(82)	(235)	(142)	(181)	(271)
others	-	-	-	-	(4)	37	-	-
CF from Fin. Activities	188	301	(215)	502	(496)	(324)	(276)	(362)
Inc(Dec) in Cash	388	588	85	(243)	(64)	(15)	(47)	2
Add: Opening Balance	276	281	268	350	101	28	80	33
Closing Balance	664	869	350	101	28	16	33	35

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

Disclosures: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority, NFAL, it's associates. Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer. etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVelox Advisory Ltd. SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SBB Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered MBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his/her/its own advisors to determine the merits and risks of such an investment. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NFAL will not treat recipien

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.